Nucleus Genomics

Nucleus Genomics is a consumer genomics company providing whole-genome sequencing-based genetic testing for family planning, health screening, and IVF embryo selection. The platform offers direct-to-consumer genetic testing that provides risk and disposition score analyses across an extensive number of diseases and traits, including cancers, diabetes, heart disease, Alzheimer’s disease, height, intelligence, and eye color. For couples planning a family, Nucleus Preview screens for hereditary diseases and predicts traits of future children. For IVF patients, Nucleus Embryo helps select embryos by screening for chronic health risks including cancers, diabetes, and rare diseases, while also predicting physical traits. The company’s Origin platform represents a family of the most predictive genetic models ever built, trusted by over 165 clinics worldwide. Nucleus partners with fertility clinics including Neway Fertility and Beverly Hills Fertility. Founded in 2021 and headquartered in Manhattan, New York, the company has raised approximately $32 million in Series A funding. Investors include Seven Seven Six, Founders Fund, Shrug Capital, Pareto, Quiet Capital, and Neo. The company has approximately 43 employees.